Skip to main content
. 2018 Jan 22;53(5):3528–3548. doi: 10.1111/1475-6773.12823

Figure 2.

Figure 2

Descriptive Trends in Provider‐Administered Cancer Drugs [Color figure can be viewed at http://wileyonlinelibrary.com]
  • Notes: Data are from beneficiaries in markets (Hospital Referral Region) that had no 340B hospital before the study period; *Among patients who received any provider‐administered cancer drug; Inline graphic treatment group includes beneficiaries from markets that newly gained a 340B hospital during the study period; Inline graphic control group includes beneficiaries in markets with no 340B hospital.